


Furadantin Suspension

(nitrofurantoin)

To prevent lower urinary tract reinfection
in childhood



Furadantin Suspension, the only liquid form of nitrofurantoin, is recommended for recurrent U.T.I. in childhood because it is bactericidal and specific to the urinary tract, being active in both the urine and the renal medulla.

Furadantin Suspension is rapidly absorbed in the G.I. tract and does not cause changes in the gut flora.

when used prophylactically in susceptible individuals

Further information is available on request to the company.

PL 0364/0010 PA 170/5/3

Furadantin is a registered trade mark.



Eaton Laboratories
Regent House, Woking, Surrey GU21 5AP

TWO NEW BOOKS FROM CHURCHILL LIVINGSTONE

CHILD ABUSE: PREDICTION, PREVENTION AND FOLLOW-UP

Edited by **Alfred White Franklin**

228 pages black and white line illustrations £8.00

This book is based on the papers and discussions presented at the Tunbridge Wells Study Group on non-accidental injury to children. Attention was focused on the identification of vulnerable families and on the prevention of child abuse.

All those concerned with this problem, particularly paediatricians and general practitioners will find this book invaluable.

ESSENTIALS OF PAEDIATRIC GASTROENTEROLOGY

Edited by **J. T. Harries**

384 pages illustrated £11.00

This book is arranged in three parts. The first deals with the prenatal development of structure and function with particular emphasis on the small gut, and an account of the currently available investigatory techniques.

The second part of the book considers a variety of conditions but, in the main, is orientated towards the alimentary tract.

The third part is devoted to disorders of the liver and pancreas in childhood.

23 Ravelston Terrace
Edinburgh EH4 3TL



Churchill Livingstone

Human Growth and its Disorders

W. A. Marshall

December 1977, xvi+180 pp. £6.80/\$13.25

0.12.47395

This book is concerned with the nature, extent and causes of variation in the physical growth and development of children whether they be healthy, or are suffering from malfunction or disease. It describes the methods of studying growth in individuals and populations and the construction of growth "standards", which are equally necessary both to clinicians who wish to decide whether a patient is growing satisfactorily and to those responsible for monitoring the health of populations of children and advising on the effectiveness of measures to improve their nutrition or freedom from disease. These "standards" form the basis for detecting abnormal growth and distinguishing pathological states from the extremes of variation.

Contents

Methods of studying growth. Variations in the growth of normal children. Detection of abnormal growth. Puberty. Maturity and its measurement. Body composition and growth of individual tissues. Interaction of heredity and environment in relation to growth. Hormones in the regulation of growth and development. Short stature: differential diagnosis and treatment. Tall children: differential diagnosis and treatment. References. Appendix. Subject index.

Academic Press

London New York San Francisco

A Subsidiary of Harcourt Brace Jovanovich, Publishers

24-28 Oval Road, London NW1, England

111 Fifth Avenue, New York, NY 10003, USA



Product Change
Announcement

Improved dietary management of phenylketonuria



Aminogran Food Supplement Aminogran Mineral Mixture

Allen & Hanburys Ltd., pioneers in the development of products for the dietary management of phenylketonuria, are now able to announce important modifications to Aminogran, already well established as an advance in therapy.

- * Separate packs obviating wastage of mineral mixture.
- * Larger packs providing a more convenient and practical supply unit.
- * New mineral mixture formulation in line with recent research findings.¹
- * New dosage recommendations allowing use of the product from infancy.²

1 Lawson et al (*Arch. Dis. Childh.* 1977 5262)

2 See new Data Sheet for details.

Aminogran Food Supplement

A mixture of L-amino acids, including all the essential amino acids except phenylalanine. In packs of 500g.

Aminogran Mineral Mixture

All the necessary minerals plus trace elements for balanced nutrition in the correct proportions for human needs. In packs of 250g.

Data Sheets and Monograph giving full prescribing information are available on request.



Aminogran is a trade mark of
ALLEN & HANBURYS LTD LONDON E2 6LA

Lioresal[®]

Relieves spasticity due to

"... has become the agent of choice for the treatment of spinal spasticity..."¹

"... drug therapy for spinal spasticity has been revolutionised by baclofen (Lioresal)."¹

"... regarded by many as the drug of choice in the treatment of spasticity due to spinal cord lesions..."²

Now also indicated for

**Spasticity
associated with
cerebral palsy
and other
allied conditions**

C I B A

Packs

Lioresal is supplied as 10mg tablets of baclofen in packs of 100.

References

1. Practical Therapeutics (1975) 10, 112.
2. Postgraduate Medical Journal (1975) 51, 615.

^{*}denotes registered trademark

Full prescribing information is available on request from

CIBA Laboratories, Horsham, West Sussex.

L/2

HILLINGDON HOSPITAL

NEONATAL UNIT

PLASMA BILIRUBIN LEVELS

PLASMA BILIRUBIN ESTIMATIONS X

NOTE:—


400 μ mol/l = 23.4 mg/100 ml

300 μ mol/l = 17.5 mg/100 ml


200 μ mol/l = 11.7 mg/100 ml

100 μ mol/l = 5.8 mg/100 ml

17.1 μ mol/l = 1.0 mg/100 ml



A new cutaneous pO_2 monitor from Kontron



This new technique is being used on an increasing scale to supplement blood gas analysis of high risk neonates by continuously monitoring and recording cutaneous pO_2 via a temperature-stable, non-invasive sensor.

Features of the new instrument include:

- ✿ Built in chart recorder
- ✿ Dual temperature setting for sensor $43^{\circ}C$ or $44^{\circ}C$
- ✿ Rapid response to changes in oxygen partial pressure
- ✿ Maximum/minimum alarm call

For demonstrations and full information about this Monitor, please complete the slip below and post to Dr. Peter Hargreaves, Kontron Instruments Limited, PO Box 188, Watford WD2 4YX, or telephone Dr. Hargreaves at Watford (0923) 47666.

Please contact me to arrange a demonstration of the Kontron pO_2 Monitor*

Please send me further information about the pO_2 Monitor*


*delete as appropriate

Name Position

Address

..... Telephone No. ADC1

KONTRON
serving hospitals throughout the world



Monatsschrift für Kinder- heilkunde

Organ der Deutschen Gesellschaft für Kinderheilkunde

125. Band · Heft 11 · November 1977

Übersichten

U. Knoop

Maßnahmen beim schweren Asthmaanfall im Kindesalter (Management of Severe Asthma in Childhood) 901

W. Ehrengut

Neurale Komplikationen nach Pertussis-Schutzimpfung (Neurological Complications Following Whooping-Cough Vaccination) 908

P. Koepp

Coma diabeticum — neues Therapiekonzept (Diabetic Ketoacidosis: New Therapeutic Regimen) 912

Originalien

A. Sychtówy, A. Dyduch, P. Dziuba, W. Maruszewski

Freisetzung von Histamin aus Leukozyten. Untersuchungen an Kindern mit Bronchialasthma, allergischem Nasenkatarrh und Urticaria (Histamine Release from Human Leukocytes in Children with Bronchial Asthma, Allergic Rhinitis and Urticaria) 914

R. Bickenbach, M. Albani, R. Ansorg

Pharmakokinetische Untersuchungen zur Gentamycin-Dosierung bei Frühgeborenen (Studies on Pharmacokinetics of Gentamicin in Premature Infants) 917

D. Karch, I. Sprock, P. Lemburg

Früherkennung schwerer Cerebralschäden bei Früh- und Neugeborenen unter Intensivtherapie. Eine polygraphische Untersuchung (Early Diagnosis

of Severe Brain Damage of Premature and Newborn Infants under Intensive Care. A Polygraphic Study) 923

H. Stolley, W. Droese, M. Kersting

Energie- und Nährstoffversorgung im Verlauf der Kindheit. I. Nahrungsmenge und Energie (Energy and Nutrient Supply During Childhood. I. Food Intake and Energy Supply) 929

G.-J. Stock, E. Gladtko

Glukose beim Neugeborenen. Eine kinetische Studie (Glucose in the Newborn. A Kinetic Study) 935

Kasuistik

E. Schober, M. Götz, S. Scheibenreiter

Treacher-Collins-Syndrom. Franceschetti-Klein-Syndrom (Treacher-Collins-Syndrome) 938

M. Ranke, J. Nothjunge, H. Mentzel

Kongenitale Struma bei einem Frühgeborenen nach Amniographie (Congenital Goiter in a Premature Infant after Amniography) 941

Aktuelle Fragen

H. Kuhlendahl, A. Laufs

Resolution zu Fragen des ärztlichen Berufsgeheimnisses (Resolution on the Question of Professional Secrets in Medicine) 944

Buchbesprechungen 945

Tagesgeschichte 946

Indexed in Current Contents

Annual subscription: DM 154,- plus postage



Springer-Verlag Berlin Heidelberg New York

Maschr. Kinderheilk. ISSN 0026-9298 MOKIAY 125 (11) 901-946 (1977)

NOVO

A few facts about monocomponent insulin from Europe's largest insulin manufacturer.

MC

means monocomponent,
a designation unique to Novo insulins.

MC

means a level of insulin purity
unequalled by any other manufacturer
and characterised by
the following specification:

a-component	not detectable
Proinsulin like substances	<1ppm
Glucagon like substances	<1ppm
Pancreatic polypeptide	<0.01ppm
Somatostatin	<0.01ppm
VIP (vasoactive intestinal polypeptide)	<0.01ppm

MC

means a range of insulins
providing a unique combination
of purity and flexibility
of administration.

MC

		0	2	4	6	8	10	12	14	16	18	20	22	24
Actrapid® MC	Rapid effect													
Semitard® MC	Intermediate effect													
Monotard® MC	Protracted effect													

NOVO INDUSTRI AS
Copenhagen, Denmark

For further information (incl. data sheets) please write to:

NOVO LABORATORIES LTD
Ringway House, Bell Road,
Daneshill East, Basingstoke, Hampshire RG24 0QN.

